BACKGROUND Cronkhite-Canada syndrome(CCS)is a rare,non-genetic disorder characterized by multiple gastrointestinal polyps,and ectodermal lesions such as alopecia,fingernail atrophy,and skin mucosal pigmentation.Unfort...BACKGROUND Cronkhite-Canada syndrome(CCS)is a rare,non-genetic disorder characterized by multiple gastrointestinal polyps,and ectodermal lesions such as alopecia,fingernail atrophy,and skin mucosal pigmentation.Unfortunately,the pathogenesis of CCS is currently unknown.CASE SUMMARY Here,we describe the case of an elderly female with diarrhea,fatigue,and hair loss,who experienced abdominal pain for over half a year and was found to have multiple gastrointestinal polyps.She was diagnosed with CCS and was treated with albumin supplementation and prednisone,and her electrolyte imbalance was corrected.Following treatment,her symptoms significantly improved.To elucidate the role of potential genetic events in the pathogenesis of CCS,we performed exome sequencing using an extract of her colorectal adenoma.CONCLUSION Our data revealed multiple somatic mutations and copy number variations.Our findings provide a novel insight into the potential mechanisms of CCS etiology.展开更多
The LTB of enterotoxigenic Escherichia coli (ETEC) expressed in Bifidobacterium infantis (BI) has been testified as mucosal adjuvant with co-vaccination BI-CfaB (the major fimbrial subunit) together in vivo in our pre...The LTB of enterotoxigenic Escherichia coli (ETEC) expressed in Bifidobacterium infantis (BI) has been testified as mucosal adjuvant with co-vaccination BI-CfaB (the major fimbrial subunit) together in vivo in our previous study. In order to investigate the mucosal adjuvant effect of BI-LTB to purified antigens, we oral vaccinated SD rats with recombinant BI-LTB plus OVA (rBI-LTB + OVA), and wild type BI plus OVA (wBI + OVA), OVA and PBS (Phosphate buffered saline) were vaccinated as controls, respectively. The OVA-specific sIgA in jejunal mucosa and specific IgG in serium were measured with ELISA (Enzyme-linked immunosorbent assay) and the sIgA producing cells were detected with immunohistochemistry technology (IHC) and Qwin image manipulation tools subsequently. The results shown rBI-LTB could stimulate SD rats produce high titer OVA-specific sIgA in rBI-LTB + OVA group and the OVA-specific sIgA titer in rBI-LTB + OVA group was found significant greater than that of the wBI + OVA group or OVA single group (p < 0.05). However no such significant difference was detected between the group wBI + OVA and OVA. IHC results suggested that intestinal mucosa and submucosa was the main field of sIgA secretion. These results suggested that recombinant LTB expression in BI could be used as a wide range mucosal adjuvant with different form antigens.展开更多
Many seminal advances have been made in human immunodeficiency virus(HIV)/AIDS research over the past four decades.Treatment strategies,such as gene therapy and immunotherapy,are yielding promising results to effectiv...Many seminal advances have been made in human immunodeficiency virus(HIV)/AIDS research over the past four decades.Treatment strategies,such as gene therapy and immunotherapy,are yielding promising results to effectively control HIV infection.Despite this,a cure for HIV/AIDS is not envisioned in the near future.A recently published academic study has raised awareness regarding a promising alternative therapeutic option for HIV/AIDS,referred to as“selective elimination of host cells capable of producing HIV”(SECH).Similar to the“shock and kill strategy,”the SECH approach requires the simultaneous administration of drugs targeting key mechanisms in specific cells to efficiently eliminate HIV replication-competent cellular reservoirs.Herein,we comprehensively review the specific mechanisms targeted by the SECH strategy.Briefly,the suggested cocktail of drugs should contain(i)latency reversal agents to promote the latency reversal process in replication-competent reservoir cells,(ii)pro-apoptotic and anti-autophagy drugs to induce death of infected cells through various pathways,and finally(iii)drugs that eliminate new cycles of infection by prevention of HIV attachment to host cells,and by HIV integrase inhibitor drugs.Finally,we discuss three major challenges that are likely to restrict the application of the SECH strategy in HIV/AIDS patients.展开更多
文摘BACKGROUND Cronkhite-Canada syndrome(CCS)is a rare,non-genetic disorder characterized by multiple gastrointestinal polyps,and ectodermal lesions such as alopecia,fingernail atrophy,and skin mucosal pigmentation.Unfortunately,the pathogenesis of CCS is currently unknown.CASE SUMMARY Here,we describe the case of an elderly female with diarrhea,fatigue,and hair loss,who experienced abdominal pain for over half a year and was found to have multiple gastrointestinal polyps.She was diagnosed with CCS and was treated with albumin supplementation and prednisone,and her electrolyte imbalance was corrected.Following treatment,her symptoms significantly improved.To elucidate the role of potential genetic events in the pathogenesis of CCS,we performed exome sequencing using an extract of her colorectal adenoma.CONCLUSION Our data revealed multiple somatic mutations and copy number variations.Our findings provide a novel insight into the potential mechanisms of CCS etiology.
文摘The LTB of enterotoxigenic Escherichia coli (ETEC) expressed in Bifidobacterium infantis (BI) has been testified as mucosal adjuvant with co-vaccination BI-CfaB (the major fimbrial subunit) together in vivo in our previous study. In order to investigate the mucosal adjuvant effect of BI-LTB to purified antigens, we oral vaccinated SD rats with recombinant BI-LTB plus OVA (rBI-LTB + OVA), and wild type BI plus OVA (wBI + OVA), OVA and PBS (Phosphate buffered saline) were vaccinated as controls, respectively. The OVA-specific sIgA in jejunal mucosa and specific IgG in serium were measured with ELISA (Enzyme-linked immunosorbent assay) and the sIgA producing cells were detected with immunohistochemistry technology (IHC) and Qwin image manipulation tools subsequently. The results shown rBI-LTB could stimulate SD rats produce high titer OVA-specific sIgA in rBI-LTB + OVA group and the OVA-specific sIgA titer in rBI-LTB + OVA group was found significant greater than that of the wBI + OVA group or OVA single group (p < 0.05). However no such significant difference was detected between the group wBI + OVA and OVA. IHC results suggested that intestinal mucosa and submucosa was the main field of sIgA secretion. These results suggested that recombinant LTB expression in BI could be used as a wide range mucosal adjuvant with different form antigens.
基金the Medical Research Project of Chongqing Municipal Science and Technology Bureau and Health Commission(No.2020GDRC004)the Key Medical Research Project of Chongqing Municipal Science and Technology Bureau and Health Commission(No.2019ZDXM012).
文摘Many seminal advances have been made in human immunodeficiency virus(HIV)/AIDS research over the past four decades.Treatment strategies,such as gene therapy and immunotherapy,are yielding promising results to effectively control HIV infection.Despite this,a cure for HIV/AIDS is not envisioned in the near future.A recently published academic study has raised awareness regarding a promising alternative therapeutic option for HIV/AIDS,referred to as“selective elimination of host cells capable of producing HIV”(SECH).Similar to the“shock and kill strategy,”the SECH approach requires the simultaneous administration of drugs targeting key mechanisms in specific cells to efficiently eliminate HIV replication-competent cellular reservoirs.Herein,we comprehensively review the specific mechanisms targeted by the SECH strategy.Briefly,the suggested cocktail of drugs should contain(i)latency reversal agents to promote the latency reversal process in replication-competent reservoir cells,(ii)pro-apoptotic and anti-autophagy drugs to induce death of infected cells through various pathways,and finally(iii)drugs that eliminate new cycles of infection by prevention of HIV attachment to host cells,and by HIV integrase inhibitor drugs.Finally,we discuss three major challenges that are likely to restrict the application of the SECH strategy in HIV/AIDS patients.
